What is B. Riley's Estimate for Altimmune FY2026 Earnings?

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Research analysts at B. Riley issued their FY2026 EPS estimates for shares of Altimmune in a research note issued on Monday, June 2nd. B. Riley analyst M. Mamtani anticipates that the company will post earnings per share of $0.19 for the year. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. During the same quarter last year, the company earned ($0.34) EPS.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, April 3rd. William Blair reissued a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. Finally, Wall Street Zen raised shares of Altimmune from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $20.20.

Altimmune Price Performance

Shares of ALT stock traded up $0.16 during trading hours on Thursday, reaching $5.62. The stock had a trading volume of 3,862,960 shares, compared to its average volume of 2,831,228. Altimmune has a twelve month low of $3.55 and a twelve month high of $11.16. The firm has a 50-day simple moving average of $5.10 and a 200-day simple moving average of $6.33. The firm has a market capitalization of $455.82 million, a PE ratio of -3.63 and a beta of 0.58.

Hedge Funds Weigh In On Altimmune

Several large investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its holdings in shares of Altimmune by 36.7% in the fourth quarter. SG Americas Securities LLC now owns 47,060 shares of the company's stock worth $339,000 after buying an additional 12,624 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune in the fourth quarter worth about $45,000. Steward Partners Investment Advisory LLC boosted its holdings in shares of Altimmune by 38.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 28,050 shares of the company's stock worth $202,000 after buying an additional 7,850 shares during the period. Cullen Frost Bankers Inc. acquired a new position in shares of Altimmune in the fourth quarter worth about $72,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Altimmune in the fourth quarter worth about $88,000. Institutional investors own 78.05% of the company's stock.

Insider Buying and Selling at Altimmune

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of Altimmune stock in a transaction dated Thursday, March 13th. The stock was bought at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the transaction, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.10% of the stock is owned by corporate insiders.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.